In recent years, creatine has emerged as one of the most widely utilized dietary supplements, particularly among athletes and gym enthusiasts. Celebrated chiefly for its performance-enhancing qualities—amplifying muscle strength, endurance, and recovery—creatine’s alleged anti-inflammatory properties have piqued scientific and public curiosity alike. However, a rigorous systematic review and meta-analysis led by researchers at São Paulo State University (UNESP) in Brazil challenges this popular assumption. Published in the peer-reviewed journal Frontiers in Immunology, the study scrutinizes a selection of randomized, double-blind, placebo-controlled clinical trials to examine creatine’s influence on inflammation markers within human subjects. The comprehensive analysis finds that there is currently no robust clinical evidence supporting the notion that creatine supplementation exerts meaningful anti-inflammatory effects in the general human population.
The detailed research effort, funded by the São Paulo Research Foundation (FAPESP), reflects an important step toward clarifying creatine’s biochemical and physiological roles beyond its established ergogenic benefits. While in vitro studies and animal models have hinted at potential modulatory effects on inflammatory pathways, translating these findings into clinical outcomes in humans has proven elusive. The UNESP team synthesized data extracted from eight carefully controlled clinical trials, focusing on commonly studied biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and various interleukins. Ultimately, the data reveal that reductions in inflammatory markers observed with creatine supplementation are minimal and statistically insignificant when compared to placebo controls.
Dating back to the 1990s, creatine’s capacity to boost physical performance by supporting intracellular energy metabolism—specifically through replenishing adenosine triphosphate (ATP) stores—has made it indispensable in sports nutrition. Despite these ergogenic benefits, the compound’s reputation as a multi-functional supplement has, in several contexts, been inflated beyond what current scientific evidence supports. The promise of anti-inflammatory effects, in particular, has often relied on extrapolations from laboratory and animal studies rather than large-scale human clinical research. Vitor Engrácia Valenti, principal investigator and group coordinator at UNESP’s Center for Systematic Review Studies, cautions that biochemical effects observed at the cellular level do not always translate into systemic, clinically measurable outcomes in human physiology.
Delving into the trials, some heterogeneity was evident, with a few studies indicating that short-term, high-dose creatine supplementation during intense physical activities—such as triathlons and marathon running—could modestly attenuate post-exercise inflammatory responses. These specific contexts showed decreased levels of prostaglandin E2 (PGE2), TNF-α, and interleukin-1β, suggesting a protective effect against the muscle damage and acute inflammation naturally induced by strenuous endurance events. However, these findings were context-dependent and were not consistently replicated in broader or more diverse populations, particularly among clinical cohorts such as older adults with osteoarthritis or individuals with chronic inflammatory conditions.
Interestingly, the review highlights a critical confounder present in several studies: exercise itself, independent of creatine supplementation, contributes substantially to changes in inflammatory biomarker profiles and muscle recovery processes. This factorial interplay complicates the ability to isolate creatine’s specific contributions. Molecular investigations did not demonstrate a statistically significant modulation of inflammatory pathways attributable to creatine. Similarly, clinical markers such as CRP and IL-6 exhibited only negligible reductions with creatine supplementation—a 0.41 mg/dL mean decrease in CRP and even smaller effects on IL-6—neither of which met criteria for statistical or clinical relevance.
Despite these underwhelming anti-inflammatory results, Valenti underscores that the absence of conclusive evidence does not equate to definitive proof that creatine lacks any anti-inflammatory potential. Rather, it points to the scarcity of sufficiently powered, randomized clinical trials addressing the question robustly. The authors advocate for expanded research efforts encompassing diverse populations and intervention durations to deepen scientific understanding. Such work is essential not only to verify potential benefits but also to elucidate underlying biochemical mechanisms, should they exist.
Moreover, the findings draw attention to the nuanced role of inflammation itself in physiology. Far from being inherently detrimental, acute inflammatory responses triggered by exercise are vital for muscle adaptation, repair, and remodeling. Transient elevations in cytokines and inflammatory mediators activate signaling cascades that support recovery and functional gains. Therefore, indiscriminately suppressing inflammation might paradoxically hinder performance and adaptation, raising important considerations for supplement strategy in athletic contexts.
On the safety front, the expansive review paints a reassuring picture of creatine’s tolerability and absence of serious adverse effects across multiple demographics. Athletes consuming high doses (approximately 20 grams daily over five days) experienced no significant events such as cramps, dehydration, or gastrointestinal disturbances. Similarly, clinical populations, including elderly adults engaged in strength training or individuals with osteoarthritis, showed no clinically relevant negative responses to longer-term creatine use. These findings bolster the consensus that creatine is safe and well-tolerated when used appropriately under professional guidance.
In practice, while the hopes placed on creatine’s anti-inflammatory capabilities may require tempering, its established benefits for strength and exercise performance remain intact. Creatine continues to be a valuable ergogenic aid, with potential secondary benefits in functional capacity under specific exercise regimens. Valenti emphasizes the importance of consulting health professionals—such as physicians, nutritionists, or exercise physiologists—to tailor supplementation to individual needs and conditions, thereby optimizing outcomes and minimizing risks.
The paramount contribution of this research lies in setting a clear direction for future studies. By rigorously assessing available clinical data, the study highlights critical gaps in knowledge and challenges the scientific community to pursue more definitive trials. Advancing research in this domain promises not only to clarify creatine’s capacity to modulate inflammation but also to refine supplement recommendations grounded in robust evidence.
Overall, this timely meta-analysis demystifies one of the popular claims surrounding creatine supplementation, underlining the importance of evidence-based approaches in sports nutrition and clinical practice. It exemplifies how rigorous synthesis of clinical research can guide health-related decisions, balancing enthusiasm with scientific scrutiny to promote both efficacy and safety in supplement use.
Subject of Research: Creatine supplementation and its impact on inflammation in humans.
Article Title: Impact of creatine supplementation on inflammation: evidence from a systematic review and meta-analysis of randomized double-blind placebo trials.
News Publication Date: 18-Feb-2026.
Web References:
- Study publication in Frontiers in Immunology: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1743603/full
- FAPESP funding announcement: https://bv.fapesp.br/en/auxilios/118559
Keywords: Creatine, inflammation, C-reactive protein, interleukin-6, tumor necrosis factor alpha, ergogenic aids, randomized clinical trials, exercise physiology, muscle recovery, sports nutrition, systematic review, meta-analysis.
